Primary Site >> Biliary tract Cancer
Gene >> ZHX2
| 1. | |||||||||||
| Journal: | Gut. 2003 May;52(5):706-12. | ||||||||||
| Title: | Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. | ||||||||||
| Author: | Tannapfel, A|Sommerer, F|Benicke, M|Katalinic, A|Uhlmann, D|Witzigmann, H|Hauss, J|Wittekind, C | ||||||||||
| PMID: | 12692057 | ||||||||||
| 2. | |||||||||||
| Journal: | Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G973-82. | ||||||||||
| Title: | Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. | ||||||||||
| Author: | Alpini, Gianfranco|Kanno, Noriatsu|Phinizy, Jo Lynne|Glaser, Shannon|Francis, Heather|Taffetani, Silvia|LeSage, Gene | ||||||||||
| PMID: | 14701718 | ||||||||||
| 3. | |||||||||||
| Journal: | Mod Pathol. 2004 Nov;17(11):1386-91. | ||||||||||
| Title: | The V599E BRAF mutation is uncommon in biliary tract cancers. | ||||||||||
| Author: | Goldenberg, David|Rosenbaum, Eli|Argani, Pedram|Wistuba, Ignacio I|Sidransky, David|Thuluvath, Paul J|Hidalgo, Manuel|Califano, Joseph|Maitra, Anirban | ||||||||||
| PMID: | 15181454 | ||||||||||
| 4. | |||||||||||
| Journal: | Virchows Arch. 2004 Aug;445(2):179-82. Epub 2004 Jun 19. | ||||||||||
| Title: | Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. | ||||||||||
| Author: | Saetta, Angelica A|Papanastasiou, Pollyanthi|Michalopoulos, Nikolaos V|Gigelou, Fanie|Korkolopoulou, Penelope|Bei, Thaleia|Patsouris, Efstratios | ||||||||||
| PMID: | 15221372 | ||||||||||
| 5. | |||||||||||
| Journal: | J Gastrointest Cancer. 2007;38(2-4):154-6. | ||||||||||
| Title: | Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. | ||||||||||
| Author: | LaRocca, Renato V|Hicks, Matthew D|Mull, Lennea|Foreman, Brenda | ||||||||||
| PMID: | 19089671 | ||||||||||
| 6. | |||||||||||
| Journal: | Hepatology. 2009 Dec;50(6):1861-70. | ||||||||||
| Title: | Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. | ||||||||||
| Author: | Blechacz, Boris R A|Smoot, Rory L|Bronk, Steven F|Werneburg, Nathan W|Sirica, Alphonse E|Gores, Gregory J | ||||||||||
| PMID: | 19821497 | ||||||||||
| 7. | |||||||||||
| Journal: | Curr Drug Targets. 2010 Jul;11(7):834-50. | ||||||||||
| Title: | Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. | ||||||||||
| Author: | Wiedmann, Marcus W|Mossner, Joachim | ||||||||||
| PMID: | 20388063 | ||||||||||
| 8. | |||||||||||
| Journal: | Hepatogastroenterology. 2010 May-Jun;57(99-100):426-9. | ||||||||||
| Title: | Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. | ||||||||||
| Author: | Qun, Wang|Tao, Yin | ||||||||||
| PMID: | 20698202 | ||||||||||
| 9. | |||||||||||
| Journal: | Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):133-40. | ||||||||||
| Title: | Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. | ||||||||||
| Author: | Pai, Rish K|Mojtahed, Kaveh|Pai, Reetesh K | ||||||||||
| PMID: | 21307665 | ||||||||||
| 10. | |||||||||||
| Journal: | Expert Rev Gastroenterol Hepatol. 2011 Oct;5(5):579-81. | ||||||||||
| Title: | Inhibitor of MEK1/2, selumetinib, for biliary tract cancer. | ||||||||||
| Author: | Furuse, Junji|Nagashima, Fumio | ||||||||||
| PMID: | 21910575 | ||||||||||
| 11. | |||||||||||
| Journal: | Oncol Rep. 2012 Apr;27(4):1266-76. | ||||||||||
| Title: | CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. | ||||||||||
| Author: | Yu, Jian-Hua|Zhong, Xiang-Yu|Zhang, Wei-Guang|Wang, Zhi-Dong|Dong, Qin|Tai, Sheng|Li, Hui|Cui, Yun-Fu | ||||||||||
| PMID: | 22209942 | ||||||||||
| 12. | |||||||||||
| Journal: | Invest New Drugs. 2012 Aug;30(4):1646-51. | ||||||||||
| Title: | SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. | ||||||||||
| Author: | El-Khoueiry, Anthony B|Rankin, Cathryn J|Ben-Josef, Edgar|Lenz, Heinz-Josef|Gold, Philip J|Hamilton, R Darryl|Govindarajan, Rangaswamy|Eng, Cathy|Blanke, Charles D | ||||||||||
| PMID: | 21748296 | ||||||||||
| 13. | |||||||||||
| Journal: | Hepatology. 2013 Jun;57(6):2248-60. | ||||||||||
| Title: | Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. | ||||||||||
| Author: | Cui, Xiang-Dan|Lee, Mi-Jin|Kim, Jong-Hyun|Hao, Pei-Pei|Liu, Lan|Yu, Goung-Ran|Kim, Dae-Ghon | ||||||||||
| PMID: | 23315987 | ||||||||||
| 14. | |||||||||||
| Journal: | J Pathol. 2013 Jun;230(2):165-73. | ||||||||||
| Title: | PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. | ||||||||||
| Author: | Marsh, Victoria|Davies, Emma J|Williams, Geraint T|Clarke, Alan R | ||||||||||
| PMID: | 23483557 | ||||||||||
| 15. | |||||||||||
| Journal: | J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):754-60. | ||||||||||
| Title: | Molecular mechanism of cholangiocarcinoma carcinogenesis. | ||||||||||
| Author: | Maemura, Kosei|Natsugoe, Shoji|Takao, Sonshin | ||||||||||
| PMID: | 24895231 | ||||||||||
| 16. | |||||||||||
| Journal: | Invest New Drugs. 2014 Dec;32(6):1144-54. | ||||||||||
| Title: | Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. | ||||||||||
| Author: | Ewald, Florian|Norz, Dominik|Grottke, Astrid|Hofmann, Bianca T|Nashan, Bjorn|Jucker, Manfred | ||||||||||
| PMID: | 25152244 | ||||||||||
| 17. | |||||||||||
| Journal: | BMC Cancer. 2016 Feb 11;16:90. | ||||||||||
| Title: | Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. | ||||||||||
| Author: | Cavalloni, Giuliana|Peraldo-Neia, Caterina|Sassi, Francesco|Chiorino, Giovanna|Sarotto, Ivana|Aglietta, Massimo|Leone, Francesco | ||||||||||
| PMID: | 26868125 | ||||||||||
| 18. | |||||||||||
| Journal: | Oncotarget. 2016 Jul 19;7(29):46750-46767. | ||||||||||
| Title: | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. | ||||||||||
| Author: | Chong, Dawn Q|Zhu, Andrew X | ||||||||||
| PMID: | 27102149 | ||||||||||
| 19. | |||||||||||
| Journal: | J Gastrointest Oncol. 2016 Dec;7(6):E98-E102. | ||||||||||
| Title: | Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. | ||||||||||
| Author: | Lavingia, Viraj|Fakih, Marwan | ||||||||||
| PMID: | 28078132 | ||||||||||
| 20. | |||||||||||
| Journal: | Tumour Biol. 2017 May;39(5):1010428317698359. | ||||||||||
| Title: | Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway. | ||||||||||
| Author: | Zhang, Mingdi|Cai, Shizhong|Zuo, Bin|Gong, Wei|Tang, Zhaohui|Zhou, Di|Weng, Mingzhe|Qin, Yiyu|Wang, Shouhua|Liu, Jun|Ma, Fei|Quan, Zhiwei | ||||||||||
| PMID: | 28459363 | ||||||||||
| 21. | |||||||||||
| Journal: | Oncol Lett. 2017 May;13(5):2957-2964. | ||||||||||
| Title: | A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. | ||||||||||
| Author: | Pan, Ting-Ting|Wang, Wei|Jia, Wei-Dong|Xu, Ge-Liang | ||||||||||
| PMID: | 28529557 | ||||||||||
| 22. | |||||||||||
| Journal: | Cancer Lett. 2017 Dec 28;411:162-170. | ||||||||||
| Title: | Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. | ||||||||||
| Author: | Jin, Ling|Jin, Mei-Hua|Nam, Ah-Rong|Park, Ji-Eun|Bang, Ju-Hee|Oh, Do-Youn|Bang, Yung-Jue | ||||||||||
| PMID: | 29024814 | ||||||||||
| 23. | |||||||||||
| Journal: | Oncotarget. 2017 Dec 8;8(69):113444-113459. | ||||||||||
| Title: | Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. | ||||||||||
| Author: | Yeh, Chun-Nan|Chang, Yu-Chan|Su, Yeu|Shin-Shian Hsu, Dennis|Cheng, Chi-Tung|Wu, Ren-Chin|Chung, Yi-Hsiu|Chiang, Kun-Chun|Yeh, Ta-Sen|Lu, Meng-Lun|Liu, Chun-Yu|Mu-Hsin Chang, Peter|Chen, Ming-Han|Huang, Chi-Ying F|Hsiao, Michael|Chen, Ming-Huang | ||||||||||
| PMID: | 29371921 | ||||||||||